Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli

BACKGROUND: Cisplatin has been in use for 40 years for treatment of germ line and other forms of cancer. Oxaliplatin is approved for treatment of metastatic colorectal cancer. Thirty to forty percent of cancer patients receiving these agents develop pain and sensory loss. Oxaliplatin induces distinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ta, Lauren E, Low, Philip A, Windebank, Anthony J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655284/
https://www.ncbi.nlm.nih.gov/pubmed/19245717
http://dx.doi.org/10.1186/1744-8069-5-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655284/
https://www.ncbi.nlm.nih.gov/pubmed/19245717
http://dx.doi.org/10.1186/1744-8069-5-9

Ejemplares similares